©2022 Stanford Medicine
ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain
Trial ID: NCT01834937
The purpose of this enhanced surveillance study ("ESS") is to collect information regarding chronic adverse events that are possibly related to the ExAblate® System ("ExAblate") that are received by InSightec ("InSightec") following PMA approval. This study will examine adverse events reported in patients undergoing the device procedure for the first two years of commercial experience. Other relevant data may be collected as well.
A Post Approval Registry: ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain
This study collects safety data on patient treatments performed commercially under the FDA
- Eligibility is as per approved device indication.
- All registry-consented patients who undergo commercial ExAblate procedure for bone
mets palliation after device approval.
device: ExAblate MRgFUS (Magnetic Resonance guided Focused Ultrasound Surgery)
School of Medicine
300 Pasteur Drive
Stanford, CA 94305